4th May 2006 11:53
Oxford Biomedica PLC04 May 2006 FOR IMMEDIATE RELEASE 4 MAY 2006 OXFORD BIOMEDICA ANNUAL GENERAL MEETING 2006 Oxford, UK - 4 May 2006: Oxford BioMedica (LSE: OXB), the leading gene therapycompany, announced today that all resolutions were duly passed at its AnnualGeneral Meeting, held today in London. -Ends- For further information, please contact:Oxford BioMedica plc: Tel: +44 (0)1865783 000 Professor Alan Kingsman, Chief ExecutiveCity/Financial Enquiries: Tel: +44 (0)207466 5000 Lisa Baderoon/ Mark Court/ Mary-Jane Johnson BuchananCommunicationsScientific/Trade Press Enquiries: Tel: +44 (0)207886 8150 Katja Stout/ Gemma BradleyNorthbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes two candidates in multiple Phase II trials, and a preclinical targetedantibody therapy in collaboration with Wyeth. A Phase III trial in renal cancerwith TroVax, the lead cancer immunotherapy candidate, is planned for the secondhalf of 2006. In neurotherapy, the Company's lead product is a gene therapy forParkinson's disease, which is expected to enter clinical development in 2006,and four further preclinical candidates. The Company is underpinned by over 80patent families, which represent one of the broadest patent estates in thefield. The Company has a staff of approximately 70 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet,Sigma-Aldrich, Viragen, MolMed, VIRxSYS and Kiadis; and has licensed technologyto a number of companies including Merck & Co, Biogen Idec and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica